Results: Three patterns of expression were detected. In the first, CD19, CD79a, and MPO mRNAs were less abundant than CD3e. In the second pattern, MPO mRNA was more abundant than the other three mRNAs. In the third, CD19 or CD79a was more highly expressed than CD3e and MPO. The three patterns corresponded to T-ALL, AML, and B-ALL, respectively. The use of cutoffs to establish qualitatively the pattern of coexpression of the four lineage markers provided the same
Golub et al. (1 ) showed in 1999 that it was possible to distinguish acute myeloid leukemias (AMLs) 5 from acute lymphoid leukemias (ALLs) on the basis of gene expression monitored by DNA microarrays. Among the 50 genes most closely correlated with distinction between AML and ALL, some coded for proteins critical for S-phase cell cycle progression. Some of these genes were known oncogenes, whereas others had a role in transcription or in cell adhesion. In addition, it was not surprising to find genes of cell lineage markers such as CD33 or CD11c. These lineage markers belong to a family of proteins used to distinguish the cell lineage of leukemic proliferating blasts by immunophenotyping techniques (2) (3) (4) . The presence of these lineage markers corresponds to a stage of cell differentiation.
Our objective was to investigate lineage markers in acute leukemias by reverse transcription followed by real-time quantitative-PCR (RTQ-PCR). We studied whether, at the mRNA level, the profiles of lineage marker expression enabled differential diagnosis among AML, B-lineage ALL, and T-lineage ALL. We selected four lineage markers already used in the immunophenotyping of acute leukemias. These markers are characterized by their persistent expression within the same lineage: CD19 and CD79a (B-lymphoid lineage), CD3e (T-lymphoid lineage), and myeloperoxidase (MPO; myeloid lineage). Using immunophenotyping, we interpreted these markers after enrichment of blast cells or in plain bone marrow, after gating. In our model, the profiles of these four lineage markers were studied without cell sorting.
Materials and Methods leukemic samples for rtq-pcr validation
We collected 72 bone marrow samples from adult and pediatric patients with acute leukemia at diagnosis. Diagnosis was made based on cytomorphology and cytochemistry according to the French-America-British (5-10 ) and the WHO (11, 12 ) classifications. Immunophenotyping with immunologic classification based on the proposition of The European Group for the Immunological Classification of Leukemias (13 ) confirmed the morphologybased diagnosis. Immunophenotyping was performed on the plain bone marrow aspirate after lysis of the erythrocytes. Immunophenotyping analysis was performed after manual gating around blastic populations. Results are expressed as percentages of labeled blast cells. Positivity thresholds were 30% for B-and T-lineage markers and 20% for myeloid antigens (14 ) .
Of the 72 samples, 40 were from AML, 27 were from B-ALL, and 5 were from T-ALL patients (see Data Supplement 1, which accompanies the online version of this article at http://www.clinchem.org/content/vol50/ issue7/). The median percentage of blast cells within the 40 AML bone marrow samples was 52% (range, 23-93%). These percentages ranged from 53% to 96% (median, 85%) and from 70% to 99% (median, 90%) in the B-and T-ALL samples, respectively. This first cohort of 72 patients was used to develop our technique. In a second step, this technique was validated on an additional cohort of 13 patients. Of these 13 samples of bone marrow, 8 were AML, 4 were B-lineage ALL, and 1 was T-lineage ALL. The percentages of blast cells within the bone marrow samples ranged from 32% to 92% (median, 76%).
rna preparation
After the erythrocytes were lysed, the leukocytes were obtained by centrifugation and counted in a Particle Counter ® Z1 (Coulter Corporation). Total RNA was extracted from 10 7 leukocytes with Trizol Reagent (Invitrogen) or the Tripure Isolation Reagent (Roche Diagnostics) according to the manufacturers' recommendations. The RNA concentration was measured by ultraviolet spectroscopy.
reverse transcription reaction and conditions The cDNA synthesis reaction was performed with 1 g of RNA in a volume of 20 L containing 19.95 M random hexamers, 10 mM dithiothreitol (Invitrogen), 0.5 mM deoxynucleotide triphosphates (Roche Diagnostics), 0.025 U/L Superscript Reverse Transcriptase (Invitrogen), 2 U/L Ribonuclease Inhibitor Recombinant (Rnase out; Invitrogen), and 5ϫ first-stand buffer (final dilution, 1ϫ; Invitrogen). Reverse transcription was performed for 60 min at 37°C. We diluted 10 L of the total reverse transcription volume in 990 L of nuclease-free water (Promega) and then used 5 L of this dilution for each quantitative PCR.
pcr reaction and conditions
Primers were designed to recognize specific mRNA sequences by Primer Express Software (Applied Biosystems). These primers amplified only RNA and not human genomic DNA (which can contaminate RNA preparations). For MPO, the primers recognized all splicing variants. The primer sequences used are listed in Table 1. RTQ-PCR amplification reactions were prepared with use of the SYBR ® Green PCR Core Reagent Kit (Applied Biosystems) and were analyzed on a real-time PCR instrument (GeneAmp ® 5700 Sequence Detection System; Applied Biosystems). Each RTQ-PCR was performed in a final volume of 25 L containing 5 L of the diluted cDNA, 12.5 L of SYBR Green PCR Core Reagent, 400 nM each amplification primer, and sterilized water (Baxter). Thermal cycling was started with a initial denaturation step at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 60 s. At the end of PCR, amplicon melting curves were obtained by increasing the temperature from 60 to 95°C. Each PCR reaction was performed in triplicate. The same RTQ-PCR conditions were used in the second cohort except for a modification: each PCR reaction contained 25 ng of cDNA.
pcr controls
Five positive controls (cDNA) were synthesized by PCR, according to the procedure described by Morrison et al. 
real-time quantification
RTQ-PCR were performed on GeneAmp 5700 Sequence Detection System (Applied Biosystems). Real-time quantification was based on the use of the fluorochrome Sybr Green I. Quantification of the target amount in unknown samples was performed by measuring the threshold cycle (CT) (which is defined as the fractional cycle number at which the fluorescence encounters a fixed threshold). In the 72 samples, the same threshold was used for CD3e, CD19, CD79a, MPO, and Abelson (ABL). The expression of each gene was normalized to the expression of the housekeeping gene (ABL) (16, 17 ) . The negative controls and the samples were amplified in triplicate. The calibrator was also tested for each of the five RTQ-PCR in triplicate. The reference dilution used for the calibrator was 10 3 copies of each five positive controls/5 L. The mean CT was calculated. Our results were expressed in ⌬CT (CT value of target gene minus CT value of housekeeping gene).
dna preparation
A sample of peripheral blood was taken from each of five healthy donors. The DNA was extracted according to the phenol-chloroform method (18 ) .
Results

validation of rtq-pcr
The calibrator was diluted and amplified in triplicate for each of the five target sequences. For a constant threshold, the SD obtained on the CT for various dilutions of the calibrator are illustrated in Table 2 . The SD values increased with increasing CT values. The SD were similar for all positive controls.
Real-time PCR data were analyzed according to the procedure described by Livak and Schmittgen (19, 20 ) . The variation in ⌬CT according to concentration over the range 10 -10 4 copies/5 L is shown in Table 3 . We plotted the logarithm of the input amount vs ⌬CT for each PCR amplification. A linear regression was performed for each plot. The linear regression slope for each PCR amplification is shown in Table 3 . The slopes were all Ͻ0.1.
We sometimes observed amplification curves for the negative controls for each five-positive control RTQ-PCR (with CT values of 33.0 -39.9), but in all cases, melting 
quantification by rtq-pcr
All quantitative data for the two cohorts are detailed in online Data Supplement 2. In the AML subgroup, all subtypes of AML were present except for AML-M7. In the lymphoid leukemias, all stages of differentiation described by The European Group for the Immunological Classification of Leukemias (13 ) were analyzed. Our samples also included secondary acute leukemias (5 AML with preceding myelodysplastic syndrome). No undifferentiated or biphenotypic acute leukemias were investigated in this study.
The percentage of blasts in the analyzed samples was always Ͼ20% (12 ) (online Data Supplement 2). For each sample, the morphology-based diagnosis and the expression (⌬CT) of the four lineage markers were evaluated. Three samples (39, 43 , and 50) were uninterpretable according to the CT value of the housekeeping gene. The 69 other samples were classified into two subsets according to the CT values obtained for the target genes. The first subset included samples characterized by a lineage marker CT value Ͻ30 (which corresponded to concentrations Ͼ100 copies/PCR). These samples were referred to as positive and quantifiable, and their results are expressed in terms of ⌬CT. In the second subset, the target gene CT values were Ͼ30. The results for these samples, referred to as positive and nonquantifiable, are indicated as "ϩ". To have fewer positive and nonquantifiable samples, each PCR of the second cohort of patient contained 10-fold more cDNA (25 ng/PCR), and all samples were then positive and quantifiable. For all samples, analysis of the amplicon melting curves confirmed the specificity of the amplification.
As shown in Figs. 1 and 2, which illustrate the dispersion of ⌬CT for each lineage marker, the number of samples varied among markers because positive and nonquantifiable samples were not included.
Depending on the lineage marker, the difference in expression between the highest and the lowest ⌬CT values varied from 8.7 (CD3e) to 11.2 (MPO; Fig. 1 ). The dispersion of ⌬CT values was irregular except for MPO. For CD19 and CD79a, one-half of the ⌬CT values were located in a small range (Ϫ3.6 to Ϫ1.2 and Ϫ4.7 to Ϫ1.6, respectively). For CD3e, most samples were observed in the 0.6 -3.3 range.
To isolate these samples, cutoff criteria were chosen for CD19, CD79a, and CD3e at ⌬CT values of Ϫ1, Ϫ1.5, and 0.5, respectively. For MPO, the cutoff was fixed at the median ⌬CT (Ϫ2.5). On the basis of these four cutoffs, each sample was interpreted as pass or fail (P or F in online Data Supplement 2a). Samples that were positive but nonquantifiable were listed as failed. For CD19, all AML and T-lineage ALL samples failed, and all B-lineage ALL (except for samples 41, 48, 55, 56, and 57) passed. The cutoff used for CD79a separated B-lineage ALL from other acute leukemias. For CD3e, all T-lineage ALL samples passed, but B-lineage ALL and AML samples were observed on each side of the cutoff. For MPO, all T-lineage ALL samples failed, but B-lineage ALL and AML samples were observed on each side of the median ⌬CT. Thus, with these cutoffs, none of the four lineage markers allowed acute leukemias to be differentiated correctly except for B-lineage ALL with the expression of CD79a.
We next compared the expression of the four lineage markers. Three patterns of coexpression were distinguished (Fig. 2) . In the first pattern ( Fig. 2A) , CD3e was expressed more than the other three markers (⌬CT CD3e Ͻ ⌬CT CD19 , ⌬CT CD79a , and ⌬CT MPO ). The second pattern, illustrated in Fig. 2B , expressed MPO more than the other three markers. In the third pattern (Fig. 2C) , expression of CD19 or CD79a was stronger than expression of MPO and CD3e. Each of these profiles corresponded to only one morphology-based diagnosis. The three profiles corresponded to T-ALL, AML, and B-ALL, respectively. There were, however, two exceptions. Sample 61 was associated with the second profile but corresponded to a B-lineage ALL, and sample 1 was associated with the third profile but corresponded to an AML.
In a third and final analysis of data, cutoff criteria were chosen according to morphology-based diagnosis. For CD3e, the cutoff was placed at the lower limit of the highest ⌬CT observed in T-lineage ALL. For CD19 and CD79a, cutoffs were placed at the lower limit of the highest ⌬CT observed in B-lineage ALL. The cutoff for MPO was placed at the upper limit of the lowest ⌬CT observed in B-and T-lineage ALL. Cutoffs for CD19, CD79a, CD3e, and MPO were at ⌬CT values of 1, Ϫ1.5, Ϫ2.5, and Ϫ3.5, respectively. These cutoffs, different from those established previously, allowed a second qualitative interpretation of the samples (P or F in online Data The expression of each target gene was normalized to the expression of the housekeeping gene (ABL). The y axis is arranged with Ϫ10 at the top and ϩ6 at the bottom. ⌬CT values were negatively correlated with expression; i.e., the higher the expression of a lineage marker, the lower the CT value for this marker, leading to a ⌬CT (CT value of lineage marker minus CT value of housekeeping gene) that is more negative. Cutoffs (horizontal lines) were located at ⌬CT values of Ϫ1, Ϫ1.5, 0.5, and Ϫ2.5 for CD19, CD79a, CD3e, and MPO, respectively. Supplement 2). Again, samples that were positive but nonquantifiable appeared as failed. According to these cutoffs, T-lineage ALLs were characterized by failed expression of CD19, CD79a, and MPO. The expression of CD3e passed. In AML, MPO passed and CD19, CD79a, and CD3e failed, or the four lineage markers failed. B-Lineage ALLs were characterized by passing expression of CD19 and CD79a and a failing expression of MPO and CD3e. Table 4 summarizes the four coexpression patterns of these three morphology-based diagnoses. On the 69 analyzed samples, only 1 (sample 10) could not be incorporated into one of these patterns. In this sample, CD19a and MPO passed and CD79a and CD3e failed.
A scoring system was established to classify acute leukemias. For CD19, CD79a, and CD3e, a value of 2 was assigned when a passed qualitative expression was observed. For passing qualitative expression of MPO, a value of 1 was assigned. Five scoring levels were applied as shown in Table 4 . This system identified three types of acute leukemias: B-lineage ALL (score ϭ 4); T-lineage ALL (score ϭ 2); and AML (score ϭ 0 or 1). A score of 3 corresponded to AML CD19ϩ.
This scoring system was applied in a second cohort of patients to differentiate acute leukemias. For the 13 samples analyzed, we observed 100% of correlation with the morphology-based diagnosis.
We next compared RTQ-PCR data with immunophenotyping results for the four lineage markers ( Table 5 ).
The ⌬CT values (in terms of failing or passing) and the percentages of labeled blast cells (in terms of positive or negative) were correlated according to positivity cutoffs for both techniques. The correlation for all four markers was good, but it was better for CD19 and CD3e than for MPO and CD79a: 100% vs 89 -96%.
Discussion
One advantage-and disadvantage-of SYBR Green is that it links to any double-stranded DNA. Specific PCR products and nonspecific products and/or primer-dimers are detected equally well (21 ) . In preliminary studies, we checked the specificity of our PCR amplifications by agarose gel electrophoresis, sequence analysis, and amplicon melting curve analysis. With the primers described in Table 1 , primer-dimers were reduced to concentrations (CT values, 33.0 -39.9) that was not important for target detection and quantification. Furthermore, primer-dimer T m s were different from T m s of specific amplicons. For CD19, CD79a, CD3e, MPO, and ABL amplicons, we observed T m s of 81.0, 87.0, 82.0, 87.0, and 81.0°C, respectively (Table 1) .
In view of the SD on the CT values, we estimated that experimental precision would be insufficient when the CT value was Ͼ30. Target mRNAs with such CT values were not quantified because sampling error contributed significantly to the variance in the experimental data. In the second cohort, the increased quantity of cDNA in each RTQ-PCR allowed greater sensitivity for the detection of targets genes. The formation of primer-dimers and the samples profile were not modified by this increase in cDNA quantity.
The analysis of ⌬CT at various concentrations showed no differences between the PCR efficiencies of the target genes and the housekeeping gene. This indicated that all PCRs had the same efficiencies. In agreement with the procedure of Livak and Schmittgen (19, 20 ) , the ⌬CT method can be used for the relative quantification of target gene without the need to run calibration curves on the same plate.
ABL was chosen as a housekeeping gene on the basis of two published reports (16, 17 ) .
All of the leukemic samples (except for samples 39, 43, and 50) jointly expressed CD3e, CD19, CD79a, and MPO. However, the expression of the different lineage markers differed among samples and within the same sample. This coexpression, which was observed even in samples containing many blasts, suggests the persistence of a normal cell population from bone marrow or peripheral blood (contamination during cell sampling). CD19, CD79a, CD3e, and MPO are not specific markers of leukemic cells. Moreover, RTQ-PCR is performed on the whole population of leukocytes, which is more complex than a population containing only blast cells. In addition, our technique does not allow cells to be analyzed individually, as in immunophenotyping using a gating system. The mRNA of residual normal cells and of blast cells is thus quantified together.
The CT value for the housekeeping gene in samples 39, 43, and 50 was Ͼ30, corresponding to a low concentration of RNA (or cDNA) or poor RNA (or cDNA) quality. CT values from these samples could therefore not be interpreted.
The 69 leukemic samples were classified according to the expression of each lineage marker, not simply according to the presence or absence of that marker. For CD19, the range of expression was the same for B-lineage ALL and for AML and T-lineage ALL (Fig. 1) . For CD79a, the range of expression was wider for AML and T-lineage ALL than for B-lineage ALL. The expression range for CD3e was narrower for T-lineage ALL than for AML and B-lineage ALL. In Table 1 , cutoffs were placed on the basis of visual criteria. These cutoffs would have been different if our sampling had contained more T-lineage ALL and if all of the samples had been positive and quantifiable. Because the cutoffs for CD79a, CD3e, and MPO corresponded to negative ⌬CT values, samples that were positive but nonquantifiable were interpreted as failed in online Data Supplement 2a. Because these samples had one target gene CT value Ͼ30 and a CT value for the housekeeping gene Ͻ30, ⌬CT values were positive and were located under these cutoffs in the samples with failed expression. For CD19, the ⌬CT of positive and nonquantifiable samples were calculated without a quantification limit. All of theses samples had a ⌬CT CD19 Ͼ2 and were located in the group with failed expression.
Because the use of these cutoffs did not allow differentiation of acute leukemias, the coexpression profile of the four lineage markers was studied. In this second approach we also worked without knowing the morphology-based diagnosis of the samples. As shown in Fig. 2 , three profiles were observed. Each profile corresponded to only one pathology, except for samples 1 and 61. In sample 1, CD79a was expressed more than CD3e and MPO, but the expression of CD19 and CD79a was less in this sample than in all B-lineage ALLs (Fig. 2C) . The same observation was made for sample 61. Sample 61 had an AML profile, but the expression of CD19 and CD79a was higher in this sample than in all AML samples (Fig. 2B) . Expression of MPO enzyme activity in leukemic blasts is commonly used to distinguish myeloid from lymphoid leukemias (9 ) . However, several studies have shown that 
a The samples were interpreted as pass (P) for CD19 when ⌬CT (CT CD19 Ϫ CT ABL ) was Ͻ1; for CD79a when ⌬CT (CT CD79a Ϫ CT ABL ) was less than Ϫ1.5; for CD3e when ⌬CT (CT CD3e Ϫ CT ABL ) was less than Ϫ2.5; for MPO when ⌬CT (CT MPO Ϫ CT ABL ) was less than Ϫ3.5. The samples were interpreted as fail (F) for CD19 when ⌬CT was Ͼ1; for CD79a when ⌬CT was greater than Ϫ1.5; for CD3e when ⌬CT was greater than Ϫ2.5; for MPO when ⌬CT was greater than Ϫ3.5. Among the 69 samples, four different coexpression patterns were observed, each corresponding to only one morphology-based diagnosis. A score of 2 was assigned for positive expression of CD19, CD79a, and CD3e. A score of 1 was assigned when positive MPO expression was observed. a small minority of cases of MPO enzyme-negative acute leukemia in adults and children exhibited MPO protein and/or MPO RNA in the leukemic blast cells (22) (23) (24) . Austin et al. (25 ) reported that in patients with infant B-precursor ALL (younger than 366 days of age), the leukemic lymphoblasts frequently expressed MPO at the RNA or protein level. Our sample 61 was a patient who was 396 days of age. This young patient had a BIII-ALL that expressed CD33 at the protein level as the lone myeloid marker. However, we observed that although sample 61 had an AML profile, the difference between the ⌬CT MPO (Ϫ2.84) and the ⌬CT CD79a (Ϫ2.725) was not statistically different. Sample 1 was an AML-M0. Immunophenotyping analysis confirmed the myeloid lineage assignment by positive expression of CD13, CD33, and CD117. Moreover, immunophenotyping analysis showed no lymphoid-associated antigen expression. Negative results for CD79a, CD3, and CD22 are major criteria for myeloid lineage assignment (26, 27 ) .
In the third data analysis, our approach was different. The morphology-based diagnosis for each sample and the corresponding data were known, and then cutoffs were established. With these cutoffs, four coexpression patterns were distinguished that allowed acute leukemias to be differentiated correctly. Each pattern corresponded to only one pathology. There was, however, one exception. Sample 10 could not be assigned to any of these patterns (Fig. 2B) . This sample was an AML with a t(8;21) translocation. These AMLs have a particular morphology (28 -32 ) and more frequently coexpress CD19 and CD56. Controversial findings have been described regarding the frequency and the intensity of CD19 and/or the expression of CD56 in AML with t(8;21) (33, 34 ) , and have led to questions as to whether these aberrant phenotypic features occur frequently enough to allow selection of cases for molecular screening on the basis of immunophenotyping (31 ) . With these four cutoffs, samples 1 and 61 were correctly interpreted.
None of the four selected lineage markers alone provided the necessary information to differentiate the acute leukemias by RTQ-PCR. However, the combined study of CD79a and CD3e enabled us to develop an algorithm (Fig.  3) in which the diagnosis of AML was obtained after exclusion of the diagnosis of B-and T-lineage ALL. However, such an algorithm is not applicable in routine practice because of the risk of aberrant expression of one of these two markers. A second algorithm based on the four lineage markers was thus defined to decrease the risk of aberrant expression (Fig. 4) ; this algorithm presents only one of several combinations. When the scoring system was established, we attributed a lower value to MPO than the other three lineage markers to distinguish the scoring of T-lineage ALL and the scoring of AML with strong expression of MPO. This also allowed separation of the scorings of AML CD19ϩ and B-lineage ALL. The presence of a normal cell population that also expresses these lineage markers most probably influences the results. Semiqualitative interpretation using an algorithm enables correct conclusions. Even without cell sorting, two lineage markers (CD3e and CD79a) are sufficient for this differential diagnosis.
To improve the diagnosis beyond the differentiation of the three lineages, it would be necessary to increase the number of genes studied. Although the study of the specific translocations of acute leukemias may seem obvious, other genes are most probably important for the prognosis, for residual disease follow-up, or for treatment of acute leukemias (11, (35) (36) (37) (38) (39) (40) (41) . Like low-density microarrays, RTQ-PCR allows study of several hundred genes but confers more precise quantification (42 ) . Furthermore, Fig. 3 . Algorithm based on two lineage markers.
The diagnosis was a B-lineage ALL if the ⌬CT value of CD79a passed (less than Ϫ1.5). The diagnosis was a T-lineage ALL if the ⌬CT value of CD79a failed (greater than Ϫ1.5) and the ⌬CT value of CD3e passed (less than Ϫ2.5). The diagnosis was AML if the ⌬CT values of CD79a and CD3e failed (greater than Ϫ1.5 and greater than Ϫ2.5, respectively). P, pass; F, fail. Fig. 4 . Algorithm based on four lineage markers.
The diagnosis was a B-lineage ALL if the ⌬CT values of CD19 and CD79a passed (Ͻ1 and less than Ϫ1.5, respectively). The diagnosis was a T-lineage ALL if the ⌬CT values of CD19 and MPO failed (Ͼ1 and greater than Ϫ3.5, respectively) and the ⌬CT value of CD3e passed (less than Ϫ2.5). The diagnosis was AML if the ⌬CT value of CD19 failed (Ͼ1) and the ⌬CT value of MPO passed (less than Ϫ3.5) or if the ⌬CT values of CD19, MPO, and CD3e failed (Ͼ1, greater than Ϫ3.5, and greater than Ϫ2.5, respectively). P, pass; F, fail.
RTQ-PCR uses very little cDNA in each reaction. Our approach would perhaps be of help in classifying cases in which cytomorphology and immunophenotyping are inconclusive in establishing the cell lineage. We could imagine the inclusion of a "lineage expression panel" in a RTQ-PCR screening plate already used for detection of fusion transcripts.
In conclusion, the study of four lineage markers by RTQ-PCR enables the differential diagnosis of AML, B-lineage ALL, and T-lineage ALL to be made without cell sorting, even when the sample contains few blasts. The lowest percentages of blasts necessary to adequately differentiate the various acute leukemias are 23%, 53%, and 66% for AML, B-lineage ALL, and T-lineage ALL, respectively. These limits are based on the percentages of blasts observed in our two cohorts at the time of cytomorphologic analysis (online Data Supplement 2). Dilutions of leukemic samples by normal bone marrow would be necessary to define the lowest limit for each type of acute leukemia. The dispersion observed in each profile is most probably the result of the absence of cell sorting. In spite of this dispersion and with a few exceptions, the coexpression profile established with cutoffs or by comparison of the four ⌬CT values provides the same information. Many questions remain to be solved. Currently, we are studying the expression profiles of these four lineage markers in peripheral blood and in bone marrow of healthy donors. We would like to know how the persistence of a normal cell population influences the results. Despite the absence of cell sorting in RTQ-PCR analysis and without considering the CV of the immunophenotyping technique, the correlation between the semiquantitative expression at the mRNA and protein levels was 89 -100%, according to lineage marker. Currently we are comparing the quantitative expression profiles of these four lineage markers at the mRNA and protein levels (with and without gating), and we are especially interested in a comparison between the ⌬CT and the median fluorescence intensity.
